Scientific Presentations

date	document
Jun 10 \| 2022	ASCO 2022: TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Patients With Renal Cell Carcinoma
Jun 10 \| 2022	ASCO 2022: Activity of Tivozanib in Non-Clear Cell Renal Cell Carcinoma (nccRCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial
Jun 10 \| 2022	ASCO 2022: Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up
Feb 14 \| 2022	ASCO GU 2022: TiNivo-2: A Phase 3, Randomized, Controlled, Open-Label Study to Compare Tivozanib in Combo With Nivolumab to Tivozanib Monotherapy in Patients With RCC Following 1 or 2 Lines of Therapy in Which at Least One Line Has an Immune CPI
Feb 14 \| 2022	ASCO GU 2022: Long-Term PFS From TIVO-3: Tivozanib (TIVO) vs Sorafenib (SOR) in Relapsed/Refractory (R/R) Advanced RCC
Jan 26 \| 2022	ASCO GI 2022: A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder, and biliary cancers
Jan 24 \| 2022	ASCO GI 2022: A Phase 1b/2 Open Label Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma: DEDUCTIVE
Jan 24 \| 2022	ASCO GI 2022: A Phase 1b/2 Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma (DEDUCTIVE): Efficacy Results in Previously Untreated Patients
Jun 4 \| 2021	ASCO 2021: Randomized Phase II Trial of Ficlatuzumab with or without Cetuximab in Pan-Refractory, Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Jun 4 \| 2021	ASCO 2021: TIVO-3: Durability of Response and Updated Overall Survival of Tivozanib vs Sorafenib in Metastatic Renal Cell Carcinoma (mRCC)
Jun 4 \| 2021	ASCO 2021: Temporal Characteristics of Treatment-Emergent Adverse Events and Dose Modifications With Tivozanib and Sorafenib in the Phase 3 TIVO-3 Study of Relapsed or Refractory mRCC
Feb 11 \| 2021	ASGO GU 2021: Q-TWiST analysis of tivozanib versus sorafenib in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study
Feb 11 \| 2021	ASCO GU 2021: Tivozanib in Patients with Advanced Renal Cell Carcinoma (aRCC) who have Progressed After Prior Treatment with Axitinib: Results from TIVO-3
Jan 15 \| 2021	ASCO GI 2021: DEDUCTIVE: a Study of Tivozanib in Combination with Durvalumab in Subjects with Untreated Advanced Hepatocellular Carcinoma; Phase Ib results
May 29 \| 2020	ASCO 2020: TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC)
Jan 27 \| 2020	ASCO GI 2020: Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab in Patients with Advanced Pancreatic Cancer
Nov 16 \| 2019	KCS 2019: TIVO-3: A Phase 3 Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC): Overall Survival 2-Year Update
Sep 30 \| 2019	ESMO 2019: TiNivo: Tivozanib Combined With Nivolumab Results in Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma (mRCC) – Final Results
Jun 3 \| 2019	ASCO 2019: TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
Jun 1 \| 2019	ASCO 2019: Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Apr 1 \| 2019	AACR 2019: CyFi: Results from a phase Ib expansion cohort of ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)
Feb 16 \| 2019	TIVO-3: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC)
Oct 22 \| 2018	TiNivo: Tivozanib Combined With Nivolumab: Safety and Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Oct 21 \| 2018	Randomized, Phase II Study of FiclatuzumabWith or Without Cetuximabin PatientsWith Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Feb 10 \| 2018	ASCO GU 2018: Tivozanib Combined With Nivolumab: Phase Ib/II Study in Metastatic Renal Cell Carcinoma
Jan 19 \| 2018	ASCO GI 2018: Phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
Nov 3 \| 2017	KCS 2017: TiNivo, A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma
Jun 5 \| 2017	Phase I study of the anti-HGF monoclonal antibody, ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer
Jun 5 \| 2017	ASCO 2017: CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)
Jun 4 \| 2017	ASCO 2017: Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
Jul 1 \| 2015	ESMO GI Congress 2015: Neuropilin1 may be Prognostic and Identify a Subgroup of Patients with Metastatic Colorectal Cancer who Benefit from fromTivozanib+ mFOLFOX6 Compared to Bevacizumab+ mFOLFOX6
Jun 4 \| 2015	ASCO 2015: Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: final results of a Phase 3 trial (901) and efficacy results of a second line tivozanib extension study (902)
Mar 6 \| 2015	AACR Angiogenesis 2015
Feb 20 \| 2015	Circulating neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib in metastatic clear cell renal cell carcinoma (RCC): post-hoc biomarker analysis of tivozanib RCC trials
Sep 29 \| 2014	ESMO 2014: Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
Sep 29 \| 2014	ESMO 2014: BATON-CRC: a phase 2 randomized trial comparing tivozanib + mFOLFOX6 with bevacizumab + mFOLFOX6 in stage IV metastatic colorectal cancer
Sep 29 \| 2014	ESMO 2014: Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma
May 31 \| 2014	ASCO 2014: First in human Phase 1 dose-escalation study of AV-203; #395, J. Sarantopoulos
Feb 24 \| 2013	Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib
Feb 16 \| 2013	ASCO GU 2013 Tivozanib TIVO-1 Subgroups - Abstract 354, Hutson
Feb 16 \| 2013	ASCO GU 2013 Tivozanib TIVO-1 QoL - Abstract 355, Cella
Feb 16 \| 2013	ASCO GU 2013 Tivozanib TIVO-1 Hypoxia Signature ccRCC - Abstract 361, Robinson
Feb 16 \| 2013	ASCO GU 2013 Tivozanib Study 902 Efficacy Safety - Abstract 364, Motzer
Feb 16 \| 2013	ASCO GU 2013 Tivozanib TIVO-1 Overall Survival - Abstract 350, Motzer
Oct 1 \| 2012	ESMO 2012 TAURUS Trial in Progress Poster - Nosov
Oct 1 \| 2012	ESMO 2012 TIVO-1 Safety Poster - Eisen
Oct 1 \| 2012	ESMO 2012 Tivozanib PKPD Poster - Escudier
Sep 30 \| 2012	ESMO 2012 Ficlatuzumab PKPD Poster - Baselga
Sep 29 \| 2012	ESMO 2012 Ficlatuzumab Phase 2 NSCLC Poster - Mok
Jun 2 \| 2012	ASCO 2012 - BATON-RCC Trial Overview poster
Jun 2 \| 2012	ASCO 2012 - Tivozanib + FOLFOX6 Ph1b Final Results
Jun 2 \| 2012	2012 ASCO Annual Meeting - Tivozanib Phase 3 TIVO-1 Data Oral Presentation (Abstract #4501)
Apr 3 \| 2012	AACR Annual Meeting 2012 - AV-203 PK Poster
Apr 2 \| 2012	AACR Annual Meeting 2012 - AV-203 ErbB3 Signaling Poster
Apr 1 \| 2012	AACR Annual Meeting 2012 - Tivozanib Food Effect Poster
Nov 15 \| 2011	AACR-NCI-EORTC - Tivozanib Ph1 ADME Study Poster
Nov 15 \| 2011	AACR-NCI-EORTC - Tivozanib Ph1 QTC Study Poster
Nov 13 \| 2011	AACR-NCI-EORTC - Tivozanib VEGFC Poster
Nov 6 \| 2011	EMUC 2011 - Results from Phase 1 trial of tivozanib combined with temsirolimus in patients with RCC
Jun 7 \| 2011	2011 ASCO Annual Meeting – Tivozanib Phase 2 Final Analysis Poster
Jun 7 \| 2011	2011 ASCO Annual Meeting – Tivozanib, Torisel Phase 1b Data Poster
Jun 6 \| 2011	2011 ASCO Annual Meeting – Ficlatuzumab Phase 2 Trial-in-Progress Poster
Jun 6 \| 2011	2011 ASCO Annual Meeting – Tivozanib, Paclitaxel Phase 1b Data Poster
Jun 4 \| 2011	2011 ASCO Annual Meeting – Ficlatuzumab, Gefitinib Phase 1b Data Poster
Jan 22 \| 2011	ASCO GI 2011 Tivozanib, FOLFOX6 Phase 1b Data Poster
Dec 10 \| 2010	SABCS 2010 Tivozanib, Paclitaxel Data Poster
Nov 19 \| 2010	EORTC-NCI-AACR 2010 Anti-RON Antibody Preclinical Data Poster
Nov 19 \| 2010	EORTC-NCI-AACR 2010 Tivozanib Biomarker Poster
Nov 18 \| 2010	EORTC-NCI-AACR 2010 Tivozanib,FOLFOX Data Poster
Nov 17 \| 2010	EORTC-NCI-AACR 2010 FGFR2 mAb Poster
Nov 17 \| 2010	EORTC-NCI-AACR 2010 Tivozanib, Capecitabine Preclinical Data Poster
Oct 1 \| 2010	IKCS 2010 Tivozanib Phase 2 Histologic Subtypes Poster
Oct 1 \| 2010	IKCS 2010 Tivozanib Phase 2 Hypertension Poster
Jun 7 \| 2010	ASCO 2010 Tivozanib Poster
Jun 5 \| 2010	ASCO 2010 AV-299 Poster
Apr 21 \| 2010	Notch1 Ab AACR10
Apr 20 \| 2010	Tivozanib in HIM Model AACR10
Apr 19 \| 2010	Bioinformatics Pathway Index AACR10
Apr 19 \| 2010	Tivozanib in Chimeric Models AACR10
Apr 18 \| 2010	Furin as Novel Target AACR10
Mar 5 \| 2010	2010 Genitourinary Cancers Symposium Presentation

The listed publications and presentations discuss investigational new drugs that have not been approved by the U.S. Food and Drug Administration.

Scientific Presentations

Scientific Presentations

DISCLAIMER

NON-GAAP INFORMATION